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The most widely used drugs in depression have been sin-
gle action drugs, such as specific serotonin reuptake inhib-
itors (SSRIs). More recently, drugs with a dual mechanism
of action, particularly serotonin noradrenaline reuptake
inhibitors (SNRI's), such as venlafaxine, duloxetine, and
milnacipran, have been more widely used. Several clinical
studies have now clearly demonstrated that dual action
drugs are more clinically effective than single action drugs.
The evidence supporting this will be reviewed. Also, while
there is no dose response for single action drugs, there is
for dual action drugs. The reasons for both these clinical
findings were not clear, but recent substantial progress has
been made in our understanding of the mechanism of
action of depression at both the cellular, receptor, and
intra-cellular levels. These include the interactions of cell
body receptors, synaptic receptors, synaptic neurotrans-
mitter release and uptake, as well as the intracellular
events secondary to the release and binding of neurotrans-
mitters with the second messenger systems. One of the
most relevant findings has been the close interaction at
the cell body level of noradrenaline and serotonin neu-
rons, and how these systems influence each other. Indeed,
these findings suggest that the reason for the clinical find-
ings is based upon these interactions. Additionally, possi-
ble combination treatments for treatment-resistant
depression will be discussed, as will as the very limited tri-
als supporting these possibilities. Finally, the increased
understanding of changes within the brain have implica-
tions for development of future treatments for anxiety and
depression, and these will be discussed.
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